TY - JOUR

T1 - Survival after a nationwide adoption of robotic minimally invasive surgery for early-stage cervical cancer

T2 - A population-based study

AU - Jensen, Pernille T.

AU - Schnack, Tine H.

AU - Frøding, Ligita P.

AU - Bjørn, Signe F.

AU - Lajer, Henrik

AU - Markauskas, Algirdas

AU - Jochumsen, Kirsten M.

AU - Fuglsang, Katrine

AU - Dinesen, Jacob

AU - Søgaard, Charlotte H.

AU - Søgaard-Andersen, Erik

AU - Jensen, Marianne M.

AU - Knudsen, Aage

AU - Øster, Laura H.

AU - Høgdall, Claus

PY - 2020

Y1 - 2020

N2 - Aim: Lately, the safety of minimally invasive surgery (MIS) in the treatment of cervical cancer (CC) has been questioned. This study aimed to evaluate the risk of recurrence and survival after a nationwide adoption of robotic MIS for the treatment of early-stage CC in Denmark. Methods: Population-based data on all Danish women with early-stage CC, who underwent radical hysterectomy January 1st 2005–June 30th 2017 were retrieved from the Danish Gynecologic Cancer Database and enriched with follow-up data on recurrence, death and cause of death. The cohort was divided into two groups according to the year of robotic MIS introduction at each cancer centre. Chi-squared or Fischer test, the Kaplan Meier method and multivariate Cox regression were used for comparison between groups. Results: One thousand one hundred twenty-five patients with CC were included; 530 underwent surgery before (group 1) and 595 underwent surgery after (group 2) the introduction of robotic MIS. The 5-year rate of recurrence was low: 8.2% and 6.3% (p = 0.55) in group 1 and 2, respectively. In adjusted analyses, this corresponded to a five-year disease-free survival, hazard ratio (HR) 1.23 [95% confidence interval (CI) 0.79-1.93]. No difference in site of recurrence (P = 0.19) was observed. The cumulative cancer-specific survival was 94.1% and 95.9% (P = 0.10) in group 1 and 2, respectively, corresponding to a HR 0.60 [95% CI 0.32–1.11] in adjusted analyses. Conclusion: In this population-based cohort study, the Danish nationwide adoption of robotic MIS for early-stage CC was not associated with increased risk of recurrence or reduction in survival outcomes.

AB - Aim: Lately, the safety of minimally invasive surgery (MIS) in the treatment of cervical cancer (CC) has been questioned. This study aimed to evaluate the risk of recurrence and survival after a nationwide adoption of robotic MIS for the treatment of early-stage CC in Denmark. Methods: Population-based data on all Danish women with early-stage CC, who underwent radical hysterectomy January 1st 2005–June 30th 2017 were retrieved from the Danish Gynecologic Cancer Database and enriched with follow-up data on recurrence, death and cause of death. The cohort was divided into two groups according to the year of robotic MIS introduction at each cancer centre. Chi-squared or Fischer test, the Kaplan Meier method and multivariate Cox regression were used for comparison between groups. Results: One thousand one hundred twenty-five patients with CC were included; 530 underwent surgery before (group 1) and 595 underwent surgery after (group 2) the introduction of robotic MIS. The 5-year rate of recurrence was low: 8.2% and 6.3% (p = 0.55) in group 1 and 2, respectively. In adjusted analyses, this corresponded to a five-year disease-free survival, hazard ratio (HR) 1.23 [95% confidence interval (CI) 0.79-1.93]. No difference in site of recurrence (P = 0.19) was observed. The cumulative cancer-specific survival was 94.1% and 95.9% (P = 0.10) in group 1 and 2, respectively, corresponding to a HR 0.60 [95% CI 0.32–1.11] in adjusted analyses. Conclusion: In this population-based cohort study, the Danish nationwide adoption of robotic MIS for early-stage CC was not associated with increased risk of recurrence or reduction in survival outcomes.

KW - Cancer recurrence

KW - Cancer-specific survival

KW - Cervical cancer

KW - Disease-free survival

KW - Minimally invasive surgery

KW - Overall survival

KW - Population-based study

KW - Radical hysterectomy

KW - Robotic surgery

UR - http://www.scopus.com/inward/record.url?scp=85079122269&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2019.12.020

DO - 10.1016/j.ejca.2019.12.020

M3 - Journal article

C2 - 32109850

AN - SCOPUS:85079122269

VL - 128

SP - 47

EP - 56

JO - European Journal of Cancer, Supplement

JF - European Journal of Cancer, Supplement

SN - 0959-8049

ER -